Clinical trials for eu

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44359 clinical trials with a EudraCT protocol, of which 7384 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (11,264)
Paediatric studies in scope of Art45 of the Paediatric Regulation (2,919)

11,264 result(s) found for: eu. Displaying page 211 of 564.

EudraCT Number: 2016-004758-13

Sponsor Protocol Number: CA209-934

Start Date*: 2018-05-22

Sponsor Name:University Medical Center Hamburg-Eppendorf

Full Title: Multicenter randomized controlled study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy (IMSTAR HN)

Medical condition: Locally advanced, resectable HNSCC (head and neck squamous cell carcinoma)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10060121	Squamous cell carcinoma of head and neck	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: (No results available)

EudraCT Number: 2013-004385-34

Sponsor Protocol Number: ICM_2013/09

Start Date*: 2014-05-27

Sponsor Name:Institut régional du Cancer - Montpellier - Val d'Aurelle

Full Title: Activity of Regorafenib in combination with modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in patients with advanced Biliary Tract Cancer (BTC): A Phase Ib-II trial

Medical condition: advanced Biliary Tract Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055111	Biliary cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2018-003541-42

Sponsor Protocol Number: PROICM2018-08FOL

Start Date*: 2018-12-04

Sponsor Name:Institut régional du Cancer de Montpellier

Full Title: Safety, tolerability and efficacy of regorafenib in combination with FOLFIRINOX in patients with RAS-mutated metastatic colorectal cancer: a dose-escalation, phase I/II trial - FOLFIRINOX-R

Medical condition: RAS-mutated metastatic colorectal cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004864	10052362	Metastatic colorectal cancer	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed)

Trial results: (No results available)

EudraCT Number: 2010-019587-36

Sponsor Protocol Number: DSHNHL2009-1

Start Date*: 2011-10-10

Sponsor Name:Universität des Saarlandes

Full Title: Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody rituximab, substitution of conventiona...

Medical condition: Diffuse large B-cell lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10005329 - Blood and lymphatic system disorders	10005329	Blood and lymphatic system disorders	SOC

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: (No results available)

EudraCT Number: 2019-002971-32	Sponsor Protocol Number: PROICM2019-11PRA	Start Date*: 2020-07-27
Sponsor Name:Institut Regional du Cancer de Montpellier
Full Title: A Double blind randomized phase III study of pravastatin vs placebo as primary prevention of severe subcutaneous breast fibrosis in hyper-radiosensitive identified patients with breast cancer
Medical condition: Radio-induced fibrosis in breast cancer
Disease:
Population Age: Adults, Elderly		Gender: Female
Trial protocol: FR (Completed)
Trial results: (No results available)

EudraCT Number: 2019-002805-23

Sponsor Protocol Number: IFCT-1804

Start Date*: 2020-01-07

Sponsor Name:IFCT

Full Title: A Phase II, multi-centre study, to evaluate the efficacy and safety of osimertinib treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC) with Brain or Leptomeningeal metasta...

Medical condition: EGFR-mutated Non-small cell lung cancer (NSCLC) with Brain or Leptomeningeal metastases

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	22.0	10018065 - General disorders and administration site conditions	10071975	EGFR gene mutation	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed)

Trial results: (No results available)

EudraCT Number: 2019-004359-35

Sponsor Protocol Number: ICEA2020.1

Start Date*: 2020-10-23

Sponsor Name:Leiden University Medical Center

Full Title: Induction of Cure in Early Arthritis

Medical condition: early unclassified arthritis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	10028395 - Musculoskeletal and connective tissue disorders	10062164	Seronegative arthritis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Completed)

Trial results: (No results available)

EudraCT Number: 2009-015587-34	Sponsor Protocol Number: PHRC/09-06	Start Date*: 2009-11-04
Sponsor Name:CHU de RENNES
Full Title: Etude d'impact à 3 ans sur l'état de santé, la qualité de vie et les coûts, de deux stratégies thérapeutiques (Natalizumab en perfusions mensuelles pendant 3 ans versus Mitoxantrone en induction pe...
Medical condition: Natalizumab en perfusions mensuelles pendant 3 ans versus Mitoxantrone en induction pendant 6 mois puis immunomodulateur au long cours dans les formes rémittentes "agressives" de sclérose en plaques
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: FR (Completed)
Trial results: (No results available)

EudraCT Number: 2017-002959-29

Sponsor Protocol Number: GLP1-honeymoon

Start Date*: 2018-10-15

Sponsor Name:Radboud university medical center

Full Title: Comparison of the beta cell mass during and shortly after the honeymoon phase of type 1 diabetes using Ga-68-exendin PET

Medical condition: Type 1 diabetes

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10027433 - Metabolism and nutrition disorders	10067584	Type 1 diabetes mellitus	PT

Population Age: Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: NL (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2016-000152-96	Sponsor Protocol Number: 2016-01	Start Date*: 2019-12-16
Sponsor Name:GETAID
Full Title: Intensive Treatment to Reach the target with Golimumab in ulcErative coliTis – In-TARGET
Medical condition: Moderate to severe ulcerative colitis
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: BE (Completed)
Trial results: (No results available)

EudraCT Number: 2017-002540-33	Sponsor Protocol Number: IFCT-1701	Start Date*: 2017-12-15
Sponsor Name:IFCT
Full Title: A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with PDL1-positive stage IV Non-Small C...
Medical condition: PD-L1 positive stage IV Non Small Cell Lung Cancer
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2010-024306-36

Sponsor Protocol Number: 1

Start Date*: 2011-04-07

Sponsor Name:Västra Götalandsregionen

Full Title: An exploratory study of sorafenib for patients listed for transplantation due to HCC

Medical condition: Patients >18 years with hepatocellular carcinoma, on waiting list for liver transplantation

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.1		10019829	Hepatocellular carcinoma recurrent	LLT
	12.1		10019830	Hepatocellular carcinoma resectable	LLT

Population Age: Elderly

Gender: Male, Female

Trial protocol: SE (Completed)

Trial results: (No results available)

EudraCT Number: 2017-002853-13

Sponsor Protocol Number: EWALL-BOLD

Start Date*: 2018-03-01

Sponsor Name:Goethe Universität Frankfurt

Full Title: Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Bli...

Medical condition: Patient aged 56 and 74 with CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10066109	Precursor B-lymphoblastic leukemia acute	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2021-000150-26

Sponsor Protocol Number: POLESTAR

Start Date*: 2022-02-14

Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH

Full Title: Phase IIA trial of short-term chemotherapy and pembrolizumab, followed by Pembrolizumab and Olaparib as firstline therapy in Her-2 negative gastric/gastroesophageal-junction (GEJ) Adenocarcinoma – ...

Medical condition: metastatic or advanced inoperable Her-2 negative esophagogastric adenocarcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10062878	Gastrooesophageal cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: (No results available)

EudraCT Number: 2023-000382-14	Sponsor Protocol Number: mRNA-1273-P203	Start Date*: 2023-12-29
Sponsor Name:ModernaTX, Inc.
Full Title: A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of...
Medical condition: Coronavirus Disease 2019
Disease:
Population Age: Adolescents, Under 18		Gender: Male, Female
Trial protocol: Outside EU/EEA
Trial results: View results

EudraCT Number: 2022-002453-25

Sponsor Protocol Number: MERCURI-2

Start Date*: 2023-03-07

Sponsor Name:Amsterdam UMC

Full Title: Preoperative sodium glucose cotransporter 2 inhibitors for prevention of postoperative acute kidney injury in cardiac surgery patients – a randomized, placebo-controlled, multi-centre, phase IV cli...

Medical condition: Cardiac Surgery-Associated Acute Kidney Injury

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	100000004857	10080266	Stage 1 acute kidney injury	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2022-003217-11

Sponsor Protocol Number: NL82304.058.22

Start Date*: 2023-02-24

Sponsor Name:Leiden University Medical Center

Full Title: Standard versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes after Whipple procedure (SPARROW): a multicenter, randomized controlled trial

Medical condition: Pancreatic head malignancy

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033614	Pancreatic carcinoma resectable	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10026319	Malignant neoplasm of pancreatic duct	LLT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10008597	Cholangiocarcinoma resectable	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2022-002582-15	Sponsor Protocol Number: NerHer-1	Start Date*: 2023-03-20
Sponsor Name:Medical University Graz
Full Title: Phase II Study of Neratinib and Trastuzumab +/- Vinorelbine p.o. in Pre-treated Metastatic HER2-positive Breast Cancer (Ner-Her-1)
Medical condition: Patients with histologically confirmed Human Epidermal Growth Factor Receptor 2 (HER2)-positive metastatic breast cancer (mBC) pretreated with trastuzumab, pertuzumab, and/or trastuzumab emtansine...
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: AT (Prematurely Ended)
Trial results: View results

EudraCT Number: 2008-003325-17

Sponsor Protocol Number: P080403

Start Date*: 2008-10-24

Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)

Full Title: Etude ARCTIC Comparaison randomisée 1/ d'un traitement antiplaquettaire ajusté par monitoring à un traitement standard à dose fixe pour stenting coronaire avec DES, et 2/ d'un arrêt versus poursuit...

Medical condition: Patients devant recevoir au moins un stent actif quel que soit le contexte

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10052086	Coronary arterial stent insertion	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: View results

EudraCT Number: 2018-004704-19

Sponsor Protocol Number: MK-7625A-036

Start Date*: 2019-08-28

Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc

Full Title: A Phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nos...

Medical condition: Nosocomial pneumonia

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	100000004862	10052596	Nosocomial pneumonia	LLT

Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: ES (Trial now transitioned) EE (Trial now transitioned) Outside EU/EEA GR (Trial now transitioned)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Wed Sep 10 22:03:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA